Published on 21st October 2014
Shares in drug developer Immupharma were higher after confirmation it had raised £3.4m at a premium price to help fund Phase III trials of its lead product candidate Lupuzor, a potential treatment for lupus.
URL: http://www.digitallook.com/dl/news/story/22154008/...